Christopher E Barbieri1, Arul M Chinnaiyan2, Seth P Lerner3, Charles Swanton4, Mark A Rubin5. 1. Department of Urology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center of Weill Cornell Medical College, New York, NY, USA. Electronic address: chb9074@med.cornell.edu. 2. Michigan Center for Translational Pathology, Departments of Pathology and Urology, and Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA. 3. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. 4. University College London Cancer Institute, Cancer Research UK Lung Cancer Centre of Excellence, London, UK. 5. Department of Urology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center of Weill Cornell Medical College, New York, NY, USA; Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, NY, USA.
Abstract
CONTEXT: Biomarker-driven cancer therapy, also referred to as precision oncology, has received increasing attention for its promise of improving patient outcomes by defining subsets of patients more likely to respond to various therapies. OBJECTIVE: In this collaborative review article, we examine recent literature regarding biomarker-driven therapeutics in urologic oncology, to better define the state of the field, explore the current evidence supporting utility of this approach, and gauge potential for the future. EVIDENCE ACQUISITION: We reviewed relevant literature, with a particular focus on recent studies about targeted therapy, predictors of response, and biomarker development. EVIDENCE SYNTHESIS: The recent advances in molecular profiling have led to a rapid expansion of potential biomarkers and predictive information for patients with urologic malignancies. Across disease states, distinct molecular subtypes of cancers have been identified, with the potential to inform choices of management strategy. Biomarkers predicting response to standard therapies (such as platinum-based chemotherapy) are emerging. In several malignancies (particularly renal cell carcinoma and castration-resistant prostate cancer), targeted therapy against commonly altered signaling pathways has emerged as standard of care. Finally, targeted therapy against alterations present in rare patients (less than 2%) across diseases has the potential to drastically alter patterns of care and choices of therapeutic options. CONCLUSIONS: Precision medicine has the highest potential to impact the care of patients. Prospective studies in the setting of clinical trials and standard of care therapy will help define reliable predictive biomarkers and new therapeutic targets leading to real improvement in patient outcomes. PATIENT SUMMARY: Precision oncology uses molecular information (DNA and RNA) from the individual and the tumor to match the right patient with the right treatment. Tremendous strides have been made in defining the molecular underpinnings of urologic malignancies and understanding how these predict response to treatment-this represents the future of urologic oncology.
CONTEXT: Biomarker-driven cancer therapy, also referred to as precision oncology, has received increasing attention for its promise of improving patient outcomes by defining subsets of patients more likely to respond to various therapies. OBJECTIVE: In this collaborative review article, we examine recent literature regarding biomarker-driven therapeutics in urologic oncology, to better define the state of the field, explore the current evidence supporting utility of this approach, and gauge potential for the future. EVIDENCE ACQUISITION: We reviewed relevant literature, with a particular focus on recent studies about targeted therapy, predictors of response, and biomarker development. EVIDENCE SYNTHESIS: The recent advances in molecular profiling have led to a rapid expansion of potential biomarkers and predictive information for patients with urologic malignancies. Across disease states, distinct molecular subtypes of cancers have been identified, with the potential to inform choices of management strategy. Biomarkers predicting response to standard therapies (such as platinum-based chemotherapy) are emerging. In several malignancies (particularly renal cell carcinoma and castration-resistant prostate cancer), targeted therapy against commonly altered signaling pathways has emerged as standard of care. Finally, targeted therapy against alterations present in rare patients (less than 2%) across diseases has the potential to drastically alter patterns of care and choices of therapeutic options. CONCLUSIONS: Precision medicine has the highest potential to impact the care of patients. Prospective studies in the setting of clinical trials and standard of care therapy will help define reliable predictive biomarkers and new therapeutic targets leading to real improvement in patient outcomes. PATIENT SUMMARY: Precision oncology uses molecular information (DNA and RNA) from the individual and the tumor to match the right patient with the right treatment. Tremendous strides have been made in defining the molecular underpinnings of urologic malignancies and understanding how these predict response to treatment-this represents the future of urologic oncology.
Authors: Floris H Groenendijk; Jeroen de Jong; Elisabeth E Fransen van de Putte; Magali Michaut; Andreas Schlicker; Dennis Peters; Arno Velds; Marja Nieuwland; Michel M van den Heuvel; Ron M Kerkhoven; Lodewijk F Wessels; Annegien Broeks; Bas W G van Rhijn; René Bernards; Michiel S van der Heijden Journal: Eur Urol Date: 2015-01-27 Impact factor: 20.096
Authors: Kai Lee Yap; Kazuma Kiyotani; Kenji Tamura; Tatjana Antic; Miran Jang; Magdeline Montoya; Alexa Campanile; Poh Yin Yew; Cory Ganshert; Tomoaki Fujioka; Gary D Steinberg; Peter H O'Donnell; Yusuke Nakamura Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti Journal: Clin Cancer Res Date: 2005-05-15 Impact factor: 12.531
Authors: Hikmat Al-Ahmadie; Gopa Iyer; Marcel Hohl; Saurabh Asthana; Akiko Inagaki; Nikolaus Schultz; Aphrothiti J Hanrahan; Sasinya N Scott; A Rose Brannon; Gregory C McDermott; Mono Pirun; Irina Ostrovnaya; Philip Kim; Nicholas D Socci; Agnes Viale; Gary K Schwartz; Victor Reuter; Bernard H Bochner; Jonathan E Rosenberg; Dean F Bajorin; Michael F Berger; John H J Petrini; David B Solit; Barry S Taylor Journal: Cancer Discov Date: 2014-06-16 Impact factor: 39.397
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm Journal: Cancer Res Date: 2012-11-01 Impact factor: 12.701
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau Journal: Can Urol Assoc J Date: 2018-05-31 Impact factor: 1.862
Authors: Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava Journal: Mol Cancer Res Date: 2017-06-12 Impact factor: 5.852
Authors: Ho Won Kang; Xuan Mei Piao; Hee Youn Lee; Kyeong Kim; Sung Pil Seo; Yun Sok Ha; Yeong Uk Kim; Won Tae Kim; Yong June Kim; Sang Cheol Lee; Wun Jae Kim; Eun Young Shin; Eung Gook Kim; Seok Joong Yun Journal: Investig Clin Urol Date: 2021-05-17
Authors: Maija Puhka; Maarit Takatalo; Maria-Elisa Nordberg; Sami Valkonen; Jatin Nandania; Maria Aatonen; Marjo Yliperttula; Saara Laitinen; Vidya Velagapudi; Tuomas Mirtti; Olli Kallioniemi; Antti Rannikko; Pia R-M Siljander; Taija Maria Af Hällström Journal: Theranostics Date: 2017-08-23 Impact factor: 11.556